MRC1 and neoplasm: Subsequently, MMR-deficient CRCs are tested for BRAF c.1799T>A (p.V600E) variants and MLH1 promoter methylation to improve screening specificity, as both are associated with sporadic tumours (p < 0.001) [33,34,35,36].